Rosalind Advisors Inc. Sells 238,433 Shares of ABIVAX Société Anonyme (NASDAQ:ABVX)

Rosalind Advisors Inc. decreased its position in ABIVAX Société Anonyme (NASDAQ:ABVX) by 63.0% during the third quarter, Holdings Channel.com reports. The fund owned 139,983 shares of the company’s stock after selling 238,433 shares during the quarter. ABIVAX Société Anonyme accounts for approximately 1.0% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 20th largest position. Rosalind Advisors Inc.’s holdings in ABIVAX Société Anonyme were worth $1,613,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Janus Henderson Group PLC grew its position in shares of ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after buying an additional 131,414 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in ABIVAX Société Anonyme in the first quarter valued at $81,000. abrdn plc increased its position in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares during the period. Finally, Kennedy Capital Management LLC raised its holdings in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Laidlaw initiated coverage on shares of ABIVAX Société Anonyme in a research note on Monday, July 29th. They set a “buy” rating and a $48.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.50.

ABIVAX Société Anonyme Trading Down 2.8 %

ABVX opened at $10.25 on Wednesday. ABIVAX Société Anonyme has a 12-month low of $8.75 and a 12-month high of $17.02. The stock has a fifty day simple moving average of $10.97 and a two-hundred day simple moving average of $12.44.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.